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Abstract According to International Agency for
Research on Cancer, ethanol and acetaldehyde belong to
group 1 of human carcinogens. The accurate mechanism by
which alcohol consumption enhances carcinogenesis is still
unexplained. Alcohol is oxidized primarily by alcohol
dehydrogenase (ADH) to acetaldehyde, a substance cap-
able of initiating carcinogenesis by forming adducts with
proteins and DNA and causing mutations. Next, acetalde-
hyde is metabolized by aldehyde dehydrogenase (ALDH)
to acetate. In tissues of many cancers, we can observe
significantly higher activity of total alcohol dehydrogenase
with any change in aldehyde dehydrogenase activity in
comparison with healthy cells. Moreover, in malignant
diseases of digestive system, significantly increased activ-
ity of ADH isoenzymes class I, III and IV was found. The
gynecological, brain and renal cancers exhibit increased
activity of class I ADH. ADH and ALDH can play also a
crucial regulatory role in initiation and progression of
malignant diseases by participation in retinoic acid syn-
thesis and elimination of toxic acetaldehyde. Besides,
changes of enzymes activities in tumor cells are reflected in
serum of cancer patients, which create the possibilities of
application ADH isoenzymes as cancer markers.
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Introduction
Alcohol ingestion is widespread throughout the world.
Although ethanol consumption is commonly accepted as
social activity, it is estimated that it is responsible for
3.8 % of global mortality and for 6.5 % of deaths in Eur-
ope [1]. It has been known that alcohol abuse is associated
with damaging effects on the central and peripheral ner-
vous system, liver and pancreas or myocardium. A great
number of epidemiological studies have demonstrated a
correlation between ethanol consumption and the occur-
rence of cancers in many organs. Worldwide, about 3.6 %
of all cancers were attributable to alcohol drinking and the
International Agency for Research on Cancer (IARC)
classified alcohol consumption as group 1 of human car-
cinogens [2]. A link has been established between alcohol
and cancers of oral cavity, pharynx, larynx, esophagus,
stomach, liver, pancreas, colon, rectum and breast.
There is a dose–response relationship between ethanol
and cancer risk, with results showing that the risk of cancer
increases with increasing amount of alcohol consumed [3].
The strongest association is observed for drinking, in par-
ticular regular heavy drinking. Moreover, there is no con-
sistent difference in cancer risk between different types of
alcoholic beverages [4]. The average consumption of
alcohol in Europe is more than twice the global average,
and the average number of alcohol-attributable cancer also
exceeds by far the global average [5]. There is a strong
recommendation to limit consumption of alcoholic drinks
to less than 20 g per day for men and 10 g for women
which leads to decreasing the risk of cancer about 6 % [6].
Ethanol is absorbed by the small intestine and metabo-
lized by liver in the three ways: oxidation by alcohol
dehydrogenase (ADH), cytochrome P450 2E1 and catalase.
These reactions lead to form acetaldehyde, which is
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converted into acetate by aldehyde dehydrogenase
(ALDH). The main participation in alcohol metabolism
accounts for alcohol dehydrogenase. Alcohol metabolism
with ADH leads to the generation of reduced forms of
nicotinamide adenine dinucleotide (NADH), but induction
of cytochrome P450 2E1 conveys to reactive oxygen spe-
cies production. Acetaldehyde and reactive oxygen species
combine with cell compounds which causes disturbances of
cell physiological functions. Human ADH and ALDH exist
in multiple molecular forms that have been grouped into
several classes, and the different isoenzymes have different
catalytic properties.
Many studies have shown that disturbances of the
alcohol dehydrogenase activity play an important role in
alcohol-related neoplasms, and knowledge of possible
mechanism by which alcohol effects on carcinogenesis has
increased in recent years.
Mechanism of alcohol carcinogenicity
There are a number of biological mechanisms that may
explain the link between alcohol consumption and cancer
development (Fig. 1). One theory is that exposure to high
levels of acetaldehyde is associated with alcohol-related
cancer. Acetaldehyde causes mutations and sister chro-
matid exchanges in human cells [7]. It interferes at many
sites with DNA synthesis and repair, which results in tumor
development [8]. Moreover, acetaldehyde inhibits O6-
methyl-guanyltransferase, an enzyme necessary for reacti-
vation of adducts caused by alkylating agents [9].
Acetaldehyde, by binding to DNA and cellular protein,
forms adducts, which play an important role in carcino-
genesis [10]. DNA adducts, such as N2-ethylidene-20-
deoxyguanosine, N2-ethyl-20-deoxyguanosine and 1,N2-
propano-20-deoxyguanosine, cause polymerase errors and
induce mutations in critical genes. Moreover, they can lead
to activation of proto-oncogenes, inactivation of tumor
suppressor genes in replicating cells and inhibition of many
important enzymes of DNA synthesis pathways [11]. The
formation of DNA adducts can be facilitated in the pres-
ence of amino acids, histones or polyamines, which
increased concentration we can find in tissues with hyper-
regeneration. Chronic alcohol consumption results in
induction of inflammation and metaplasia of epithelium,
causing cell damage and consequently hyper-regeneration
of tissues [12].
Chronic alcohol consumption causes the activation of
microsomal ethanol oxidizing system (MEOS) and
expression of CYP 2E1. In humans, the induction of CYP
2E1 increases 10–20 times after daily ingestion of 40 g of
ethanol just for 1 week [13]. Induction of CYP 2E1
expression is one of the central pathways by which ethanol
generates production of reactive oxygen species (ROS) [8].
Moreover, an important consequence of ethanol and
acetaldehyde oxidation is an increase in both cytosolic and
mitochondrial NADH/NAD ratios, which elevate the
activity of xanthine oxidase, a free-radical generating
enzyme. It is commonly known that ROS can cause
oxidative damage to proteins, lipids and nucleic acids. The
most reactive ROS are: superoxide, hydrogen peroxide,
hydroxyl radicals and singlet oxygen. These compounds
can cause DNA damage by oxidation bases, making breaks
in single and double strand and also by generating
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oxidative DNA adducts [9]. Moreover, ROS influence on
lipids in cell membranes causing their peroxidation. The
end products of lipid peroxidation may damage DNA
through the formation of exocyclic adducts. The main
products of lipid peroxidation are: crotonaldehyde, acro-
lein, 4-hydroxy-2-nonenal and malondialdehyde [14].
DNA modified by peroxidation products is genetically
unstable. Moreover, CYP 2E1 metabolizes various pro-
carcinogens present in diets and tobacco smoke to their
carcinogenic metabolites [15].
CYP 2E1 also degrades retinoic acid (RA) and retinol to
polar metabolites with toxic and apoptotic properties which
can promote carcinogenesis. Chronic alcohol consumption
affects also the additional aspects of vitamin A metabo-
lism, including retinol absorption, enhanced degradation in
liver and increased mobilization of retinol from the liver to
the other organs [16]. Furthermore, it has been demon-
strated that ethanol acts as a competitive inhibitor of retinol
oxidation in liver which may reduce the biosynthesis of
retinoic acid [17]. These alcohol-induced changes result in
decreasing hepatic levels of retinol, precursor of RA, the
most active form of vitamin A. Retinoic acid is particularly
important because of its effect on cellular growth, differ-
entiation and apoptosis. Tissues depleted of retinoic acid
may enter a premalignant state, characterized by low dif-
ferentiation and high degeneration. Thus, disturbances in
RA biosynthesis may provide a possible explanation for
why chronic and excessive alcohol intake is a risk for cell
proliferation and malignant transformation. Chronic alco-
hol consumption may lead also to nutritional deficiencies
(vitamin A, vitamin C, zinc, iron and folate) by impaired
intestinal absorption and by changes in metabolic path-
ways. The most visible effect seems to be on folate, vita-
min B12 and vitamin B6 metabolism, resulting in further
changes in DNA-methylation pathways [18]. Inhibition of
trans-methylation results in disturbances in the activity of
genes entangled in carcinogenesis.
Alcohol-related cancers are difficult to cure because
ethanol consumption influences chemotherapeutic agent
metabolism which results in a decreasing response to
medication and increase in side effects. Moreover, during
cancer development, alcohol consumption may contribute
to inflammatory and immunosuppressive environments,
thus allowing tumor cells to propagate and spread [20].
Ethanol can also accelerate tumor growth and stimulates
progression probably due to induction of angiogenesis.
Alcohol consumption causes up-regulation of the expres-
sion of vascular endothelial growth factor (VEGF) which
affects the increase in both tumor size and intratumoral
vascular volume density [19]. Furthermore, alcohol may
affect the stem cell niche by perturbing many biochemical
or signaling pathways (prolactin/growth hormone (GH),
the IGF-1, estrogen receptor (ER), TGF-b, integrins,
telomerase) known to be important for both stem cells and
cancers. Alcohol and its metabolites may interfere with the
renewal or differentiation of stem cells or cancer stem cells
by affecting one or more of these pathways [20].
Alcohol dehydrogenase and aldehyde
dehydrogenase
The major pathway for the elimination of ethanol is its
oxidation to acetaldehyde by alcohol dehydrogenase
(ADH). Acetaldehyde transforms to acetate in the reaction
catalyzed by aldehyde dehydrogenase (ALDH). Mam-
malian ADH and ALDH constitute a complex enzyme
family, expressed in a few molecular forms, grouped into
several classes, which differ by localization, substrate
specificity, catalytic and immunological properties.
The class I isoenzymes are dimers formed with a, b and
c polypeptide subunits, encoded by three separate gene
loci: ADH1A, ADH1B and ADH1C. Genetic polymorphism
occurs in the class I isoenzymes among racial populations,
which affects the acetaldehyde production. In Asians,
polymorphism of ADH1B and ADH1C genes was associ-
ated with the development of alcoholism and susceptibility
to alcoholic liver cirrhosis [21]. ADH I is expressed mostly
in the liver but also can be found in the lungs, kidneys and
gastrointestinal tract (duodenum and colon) [22]. Class II
ADH is a homodimer (pp) encoded by ADH2 which exists
only in the liver [23]. Class III alcohol dehydrogenase (vv)
is found in every tissue and is encoded by ADH3 loci. ADH
III has the same structure and kinetic properties as glu-
tathione-dependent formaldehyde dehydrogenase [24].
Because of its localization and very high activity in
stomach, class IV ADH has been termed ‘‘gastric’’ alcohol
dehydrogenase. It is a homodimer (rr or ll) encoded by
ADH4 loci. Besides stomach, this isoenzyme is found also
in esophagus, liver, skin and cornea, but its expression is
limited [25]. The other classes of ADH are still poorly
described. ADH V is a homodimer, encoded by ADH5,
which was found in liver and epithelium of stomach
mucosa membrane [26]. Class VI is expressed in liver and
kidneys of rats and draws high analogy with mammalian
ADH V (67 %) [27].
Ethanol is the main substrate for alcohol dehydrogenase,
but its oxidation is efficient only in reaction catalyzed by
isoenzymes class I and IV. Besides alcohol, ADH I takes
part in metabolism of many aldehydes, bioamines, pros-
taglandins, steroids and x fatty acids [28]. Moreover, this
class participates in oxidation of retinol to retinal, a sub-
strate for retinoic acid biosynthesis [29]. ADH II catalyzes
oxidation of ethanol but mostly in the presence of its high
concentrations. It takes part also in retinal production, but
because of its limited localization, it catalyzes synthesis of
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retinol only in the liver [30]. Isoenzymes of class III reveal
a high affinity for endogenous long-chain alcohols and
aldehydes, but its main role is participation in the catabo-
lism of formaldehyde, produced after methanol poisoning
[31]. ADH IV is the major class taking part in first-pass
metabolism of ethanol (FPM). It constitutes a metabolic
barrier in stomach against orally receiving alcohol and
ethanol produced during bacterial fermentation. Moreover,
the activity of ADH IV in retinol metabolism is 6 times
higher than for ADH II and 14 times higher than for ADH
class I [32]. The role of ADH isoenzymes of higher classes
is still unknown.
In humans, there are multiple forms of ALDH divided
into two groups: cytoplasmic forms (ALDH I, ALDH III,
ALDH VII, ALDH VIII, ALDH IX) and mitochondrial
forms (ALDH II, ALDH IV, ALDH V, ALDH VI) [33].
ALDH I is distributed mainly in the liver and catalyzes
oxidation of acetaldehyde but also all trans- and 9-cis-
retinal [34]. Of the all isoenzymes, the mitochondrial
ALDH II plays a major role in human acetaldehyde
metabolism while the others metabolize a variety of sub-
stances. ALDH2*2, a genetic polymorphism of ALDH II is
prevalent in Asian populations, and these individuals show
high blood acetaldehyde concentrations after the intake of
only moderate alcohol amount [35]. Class III of ALDH
exhibits a high activity in stomach, lungs, liver, skin and
the cornea [36]. Recently, ALDH III was found in the
saliva, which represents a first barrier against toxic alde-
hydes present in the food [37]. The other classes of ALDH
are distributed widespread in human body but do not par-
ticipate in acetaldehyde oxidation. These isoenzymes play
a role in elimination of toxic aldehydes, which are pro-
duced during lipids peroxidation. They also participate in
metabolism of bile acids, bioamine, prostaglandin and
steroids dehydrogenation [38].
ADH and ALDH in malignant diseases
The pathophysiological bases of the alterations produced
by ethanol start obviously from its metabolism. Accumu-
lating evidences have shown that metabolism of cancer
cells differs from that of normal cells. The changes in the
activities of ethanol metabolism enzymes may be a great
importance and may, among others, influence carcinogen-
esis. The differences of the ADH, its isoenzymes and
ALDH activities between cancer patients and control
groups are given in Table 1.
Digestive system cancers
Esophagus is the organ where we can see toxic action of
ethanol as solution. Ethanol directly causes damage of
mucosa which makes easier the penetration of carcinogenic
substance. Human esophageal contains three classes of
alcohol dehydrogenase—ADH I, ADH III and ADH IV
[39]. Studies of Jelski et al. show that class IV of ADH had
the highest activity in esophageal cancer cells in compar-
ison with healthy tissue. Moreover, the total activity of
ADH was also significantly higher in cancer than in normal
mucosa [40]. Besides increase of ADH activity, ALDH
activity in esophageal cancer cells did not differ from the
healthy tissues. The much higher activity of ADH without
increasing ALDH activity suggests that esophageal cancer
cells have the higher ability to ethanol oxidizing than to
removing acetaldehyde, which may be important factor
favorable to carcinogenesis. Among all isoenzymes present
in esophageal, class IV reveals the main role in ethanol
oxidation so increased activity of this class in cancer cells
causes elevated production of acetaldehyde. Moreover, this
class of ADH takes part in the metabolism of lipid per-
oxidation products, which may also intensify carcinogen-
esis in esophageal. Changes in enzyme activity can be
reflected in serum of the patients. It have been stated that in
the sera of esophageal cancer patients the total activity of
ADH is elevated because of increased activity of its
isoenzyme class IV [41]. Probably the reason of increased
activity of ADH IV is releasing of this isoenzyme from
cancer cells.
Human gastric mucosa contains various isoenzymes of
alcohol dehydrogenase: ADH I, ADH III and ADH IV.
These isoenzymes compose a metabolic barrier against
orally taken alcohol (first-pass metabolism) and also etha-
nol produced in the course of bacterial fermentation. The
comparison of ADH activities in gastric cancer cells
showed that the highest activity was exhibited by class IV
ADH and the difference in its activity between cancer and
healthy tissue was significant. Therefore, the total activity
of ADH was also significantly higher in cancer patients
than in healthy ones. This suggests that gastric cancer cells
have much higher ability to produce acetaldehyde than to
remove it. Changes in ADH class IV activity can influence
on retinol as well as lipid peroxidation products metabo-
lism and many dietary carcinogens removal. Both distur-
bances in these processes and increase acetaldehyde
production may be a factor intensifying carcinogenesis
[42]. In the sera of gastric cancer patients, changes in ADH
activity were also certifiable. The total activity of ADH
was 40 % higher in patients with gastric cancer than in
control group. The activity of class IV ADH was also much
elevated (47 %) in cancer patients in comparison with
healthy subjects [43]. The increase activities of total ADH
and isoenzyme class IV may be explained by its high
activity in gastric cancer tissue.
Liver is an organ which is especially exposed for ethanol
and its metabolites actions because over 90 % of absorbed
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ethanol is metabolized in hepatocytes. Human liver con-
tains almost all classes of alcohol dehydrogenase, but the
highest activity reveals class I. In hepatocellular carci-
noma, the activity of ADH I was more than 26 % higher
than in healthy liver. The total activity of ADH was also
significantly elevated in cancer in comparison with normal
tissue. Moreover, the activity of ADH was much higher
than the activity of ALDH (ratio 55:1) which is not enough
to prevent acetaldehyde accumulation [44]. In the serum of
liver cancer patients, increase of ADH total activity was
found. That change was positively correlated with
increased activity of class I ADH. It is probably the result
of release of ADH I from liver cancer cells or from hep-
atocytes damaged by the tumor [45].
Colorectal cancer is the next malignant disease in
which the activity of ADH and ALDH was studied, and
the results are similar to those from hepatocellular car-
cinoma. The total activity of ADH and the ADH I activity
were significantly elevated in colorectal cancer tissue than
in healthy mucosa. It is interesting that the activity of
ALDH was significantly lower in cancer compared to
healthy cells [46]. It leads to very high disproportion in
the activities of ADH and ALDH which may result in
intensive generation of toxic acetaldehyde. All the more,
class I ADH has the highest participation in acetaldehyde
production and the activity of this isoenzyme is elevated
more than 40 % in colorectal cancer tissue than in normal
mucosa [46]. Chronic alcohol consumption decreases
retinoic acid production which also can be involved in
cell evaluation to premalignant states. One possibility to
keep the retinoic acid level normal could be the increased
expression of alcohol dehydrogenase isoenzymes. Seitz
et al. [47] have showed that in colorectal polyps ADH IV
was expressed which is normally not found in the pre-
malignant states. The changes of ADH activity in a tissue
are also reflected in the sera. In the course of colorectal
cancer, ADH I and the total ADH activity were elevated
in the serum of the patients. Moreover, there was a ten-
dency of ADH I activity to increase in accordance with
the advancement of cancer and was the highest in the IV
stage [48]. The source of that change can be releasing of
ADH I from colorectal cancer cells or from liver damaged
by metastatic disease.
Ethanol can be metabolized in the pancreas on both the
oxidative (ADH, MEOS) and non-oxidative pathways
(fatty acid ethyl ester synthetase). The metabolites of these
processes: acetaldehyde and fatty acid ethyl esters (FAEEs)
are commonly known factors causing pancreas damage and
induction of carcinogenesis. The development of pancreas
cancer can be also associated with increased activity of
class III ADH. Studies show that in the cells of pancreatic
cancer, there was significantly elevated activity of ADH
isoenzyme III in comparison with healthy tissue [49]. ADH
III does not take part in ethanol oxidation but participates
mainly in metabolism of endogenous long-chain alcohols
and aldehydes. Moreover, this class of ADH catalyzes the
oxidation of S-hydroxymethylglutathione. It may lead to
depletion of glutathione, which is a strong antioxidant
compound responding for maintenance of redox state in
cells. The consequence of decreased glutathione concen-
tration may be generation of reactive oxygen species and
induction of oxidative stress leading to cancer develop-
ment. In the sera of pancreatic cancer patients appears the
increased activity of total ADH associated with elevated
activity of its isoenzyme class III, which may be derived
from cancer cells [50].
Table 1 Activity of ADH and ALDH in cancer diseases
Cancer Activity
ADH I ADH II ADH III ADH IV ADH total ALDH
Tissue Serum Tissue Serum Tissue Serum Tissue Serum Tissue Serum Tissue Serum
Esophagus – – – – – – : : : : – –
Stomach – – – – – – : : : : – –
Liver : : – – – – – – : : : –
Pancreas – – – – : : – – – : – –
Colorectum : : – – – – – – : : ; –
Kidney : : – – – – – – : : – –
Breast ; – – – – – – – – – – –
Endometrium : : – – – – – – : : – –
Cervix : : – – – – – – : : – –
Ovary : : – – – – – – : : – –




The mechanism by which alcohol increases the risk of
cancer is associated also with some hormonal changes.
The consumption of alcoholic beverages may initiate
cancer development by enhancing the level of estrogen in
the body and affecting estrogen metabolism. Alcohol
could increase plasma estrogen levels either by promoting
the induction of aromatases, which can convert androgens
to estrogens, or by impairing the metabolism of estrogens
in liver, resulting in an accumulation of circulating
estrogen [51]. Human uterus contains ADH of class I, III
and IV isoenzymes. Study of Orywal et al. has shown that
the activity of class I ADH was significantly higher in
endometrial cancer cells than in healthy endometrium.
Therefore, the total ADH activity was also significantly
elevated in cancer tissue in comparison with normal
endometrial cells. Moreover, the activity of class I ADH
was significantly higher in premenopausal women com-
pared to postmenopausal women, both in cancer and in
healthy endometrial cells. The activity of ALDH did not
differ between studied groups [52]. A greater capability
for ethanol oxidation and less ability to remove
acetaldehyde may lead to its accumulation in endome-
trium, contributing to cancer development. In addition,
some reports have shown that the expression of ADH I
gene is regulated by sex hormones, which elevated level is
noted at women who consume ethanol, what also can be
associated with carcinogenesis in uterus [53]. The anal-
yses of ADH isoenzymes activity in the sera of endome-
trial cancer patients reveal similar correlations. The
activities both total ADH and ADH class I were signifi-
cantly higher in cancer patients compared to healthy
women and the patients with myoma uteri [54].
The next women malignant disease in which distur-
bances in ethanol metabolizing enzymes were stated is the
cervical cancer. The activity of class I ADH was signifi-
cantly higher in cervical cancer cells than in healthy
mucosa. The total ADH activity was also elevated in
cancer tissue without any changes in ALDH activity.
Moreover, the changes of ADH and ALDH were inde-
pendent from different histological types of cervical can-
cer. On the other hand, analysis of the particular ADH
isoenzymes depending on the progression stage of the
cancer showed a tendency toward increased ADH I activity
in accordance with the advancement of the disease. The
activities of both ADH I and the total ADH were signifi-
cantly higher in every stage (from I to III) of cancer
compared to the controls [55]. The difference of ADH and
ALDH activity between cancerous and healthy tissue may
cause disorders in the retinol metabolism which can
intensify carcinogenesis. This findings are consistent with
study of Song et al. [56] who demonstrated that metabolic
disturbances of retinal and retinoic acid may be involved in
cervical carcinogenesis.
Hormonal factors are involved in the etiology of ovarian
cancer, and 60 % of ovarian tumors are estrogen-receptor
positive. Alcohol consumption is correlated with endoge-
nous hormone levels. In premenopausal women, alcohol
consumption has been consistently, positively correlated
with both total estrogen level and bioavailable estrogens,
but postmenopausal alcoholics have elevated levels of
serum estradiol and plasma levels of estrone sulfate [57,
58]. Similar to findings in the endometrial and cervical
cancer, the activity of ADH (especially ADH class I) was
significantly higher in ovarian cancer tissue than in ovarian
cysts and healthy ovary, but the activity of ALDH was not
changed [59]. This suggests increased ability to produce
acetaldehyde by cancerous ovarian cells. Acetaldehyde
interferes with DNA synthesis and repair causing inhibition
in the O6-methylguanine-DNA methyltransferase (MGMT)
activity, which can be involved in cancer pathogenesis [9].
Moreover, many studies indicate that the retinoic acid
pathway plays a role also in ovarian carcinogenesis.
Alcohol exposure may lower RA levels either by blocking
alcohol dehydrogenase-activated RA biosynthesis due to
the competition, as dehydrogenase substrates, between
alcohol and vitamin A [16]. Disturbances between ADH
and ALDH activities in cancer cells and not-cancerous
ovarian tissues can be a factor entangled in ovary car-
cinogenesis. Besides, cancer cells can release enzymes and
change enzymatic profile in the sera of the patients.
The other cancers
The role of alcohol consumption in the increased incidence
rates of renal cancer (RCC) has been inconsistent. Most of
the studies provide supportive evidence of a negative
association between alcohol intake and risk of RCC, which
is associated with the diuretic effect of alcoholic beverages
causing reduction in the concentration of carcinogens and
decrease in time of its contact with renal epithelial cells
[60]. Only one cohort study suggested that intermediate
and heavy drinking can be associated with carcinogenesis
in kidney [61]. In renal cancer cells, there was a signifi-
cantly higher activity of total alcohol dehydrogenase and
ADH class I compared to healthy kidney; however, the
activity of ALDH was not different between both tissues
types. Moreover, the activity of total ADH and ADH I
isoenzyme was found to be significantly higher already in
patients in II stage of renal cancer [62]. These findings
suggest increased ability to produce acetaldehyde by
cancerous renal cells, already at the beginning of the dis-
ease, compared to normal renal tissue, which can cause or
intensify carcinogenesis in this organ. The increase in
enzyme activity in RCC tissue is reflected by increased
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activity in sera of cancer patients. The increase in total
ADH and ADH I activity in sera of renal cancer patients
was positively correlated with increased activity in cancer
cells, which suggests that tumor cells can release this
enzyme. Moreover, increase in ADH total and ADH I
activity in every stage of renal cancer (II–IV) suggests that
these enzymes could indicate the presence of the neoplasm.
Also the serum activity of ADH total and ADH I tended to
be higher in renal cancer patients with a more advanced
stage (article in press).
In epidemiological studies, the consumption of alcohol
has been identified as a risk factor for breast cancer but the
mechanism of this correlation is unclear. One hypothesis is
associated with disorders in reproductive steroid hormone
concentration caused by ethanol consumption, and the
second is related to toxic acetaldehyde affecting damage to
epithelial cells of the breast gland [63]. The activity of
alcohol and aldehyde dehydrogenase in the breast cancer
was also the subject of research of Jelski et al. It is inter-
esting that findings in this type of cancer show inverse
association than that which occurs in many malignant dis-
eases. The activity of class I ADH was significantly lower in
breast cancer tissue than in healthy parenchyma. Moreover,
ADH I activity in the tumor cells were decreasing together
with the progression of the disease and in invasive stage was
two times lower than in normal mammary tissue [64]. The
reduction in the ability of enzymes needed for ethanol
detoxification can lead to redox changes and metabolic
disorders and contribute to carcinogenesis. Some studies
suggest that there is a relationship between an excess of
aldehyde products of lipid peroxidation and carcinogenesis
of the breast gland so decreased activity of ADH I causes
the loss of its protective role in this process [65]. The
curious findings refer also to the sera of breast cancer
women. The activity of ADH I was significantly higher in
the sera of patients only with stage IV breast cancer as
compared to healthy controls. However, probably this was a
result of isoenzymes being released from organs damaged
by metastatic disease, e.g., liver [66].
Alcohol is capable of traversing the blood–brain barrier,
and many toxic effects of ethanol are mediated by the
acetaldehyde and thus can be a possible risk factor for brain
cancer [3]. It is found that alcohol metabolism in brain
depends mostly on catalase and cytochrome P450 2E1 and
only in 20 % on oxidation with alcohol dehydrogenase [67].
However, in brain cancer tissue the activities of ADH and
ADH I were significantly higher than in healthy brain cells
and the activity of ALDH was not different between both
tissues [68]. The level of acetaldehyde depends on the bal-
ance between ADH and ALDH, so these findings suggest that
the brain cancer cells have the higher ability to ethanol
oxidation and the less capability to removing acetaldehyde.
The differences between histological types and the
localization of brain cancers were not found [68]. Similar to
brain cancer tissue, the activities of total ADH and ADH I
were significantly higher in the sera of patients with brain
cancer compared to control group with no differences
between histological types and cancer localization [69].
Elevated activity in the sera of brain cancer patients of the
same isoenzyme where high activity was found in cancer
cells seems to be the result of its releasing from tumor cells.
Summary
Alcohol consumption is a risk factor for many malignant
diseases. The exact mechanism of ethanol-associated car-
cinogenesis has remained unknown. One of the hypotheses
is that increased ethanol metabolism leads to elevated
production of carcinogenic acetaldehyde. In the cells of
many cancers, the elevated activity of alcohol dehydroge-
nase was found compared to healthy tissue. Moreover,
there was a disproportion between activities of ADH and
ALDH, which leads to increased ability for ethanol oxi-
dation and less capability to remove acetaldehyde which
results in its accumulation and intensification of carcino-
genesis. The changes in the activities of particular isoen-
zymes can have also influence on cancer development
because of causing disorders in the metabolism of many
biologically important substances. Besides, the cancer cells
of many organs may release ADH isoenzymes to the blood
which is the reason of elevated activity of the specific
isoenzymes in the sera of cancer patients. The significant
increase of these isoenzymes in the sera creates the pos-
sibility of application ADH activity measurement in the
cancer diagnostics.
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